# Study to Evaluate the Effect of Nicotinamide Mononucleotide (NMN) As an Adjuvant to Standard of Care (SOC) On Fatigue Associated With COVID-19 Infection

> **NCT05175768** · NA · TERMINATED · sponsor: **Vedic Lifesciences Pvt. Ltd.** · enrollment: 69 (actual)

## Conditions studied

- COVID-19 Infection

## Interventions

- **OTHER:** Nicotinamide Mononucleotide
- **OTHER:** Nicotinamide Mononucleotide with L-Leucine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05175768
- **Lead sponsor:** Vedic Lifesciences Pvt. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-27
- **Primary completion:** 2022-07-16
- **Final completion:** 2022-07-16
- **Target enrollment:** 69 (ACTUAL)
- **Why stopped:** Required criteria of covid patient was not met
- **Last updated:** 2024-09-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05175768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05175768, "Study to Evaluate the Effect of Nicotinamide Mononucleotide (NMN) As an Adjuvant to Standard of Care (SOC) On Fatigue Associated With COVID-19 Infection". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05175768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*